open access

Vol 6, No 6 (2017)
CASE REPORT
Published online: 2018-01-26
Get Citation

Improvement of type 2 diabetes mellitus control with hydroxychloroquine added to triple oral antidiabetis drugs: a case report

Subash Chandra Satpathy, Indranil Purkait, Avinash Talware
DOI: 10.5603/DK.2017.0034
·
Clinical Diabetology 2017;6(6):211-214.

open access

Vol 6, No 6 (2017)
CASE REPORT
Published online: 2018-01-26

Abstract

Hydroxychloroquine, an antimalarial drug has also been found to possess antidiabetic action. It inactivates insulin degradation enzymes and also delays the dis­sociation of insulin from the insulin receptor thus also lowering the insulin resistance and increasing insulin sensitivity. Here we report a case of a male patient with uncontrolled type 2 diabetes mellitus (T2DM) who obtained a better glycemic control when hydroxychlo­roquine was added to the existing pharmacotherapy. The patient has been taking metformin, glimepiride and acarbose for the last 2 years but his diabetes was poorly controlled with glycated haemoglobin (HbA1c) of 9.6%. Patient was proposed to intensify the treatment with insulin however he refused it. He was subsequently prescribed hydroxychloroquine 400 mg. Patient responded well to the therapy of hydroxy­chloroquine and subsequent follow-ups showed good glycaemic control. (Clin Diabetol 2017; 6, 6: 211–214)

Abstract

Hydroxychloroquine, an antimalarial drug has also been found to possess antidiabetic action. It inactivates insulin degradation enzymes and also delays the dis­sociation of insulin from the insulin receptor thus also lowering the insulin resistance and increasing insulin sensitivity. Here we report a case of a male patient with uncontrolled type 2 diabetes mellitus (T2DM) who obtained a better glycemic control when hydroxychlo­roquine was added to the existing pharmacotherapy. The patient has been taking metformin, glimepiride and acarbose for the last 2 years but his diabetes was poorly controlled with glycated haemoglobin (HbA1c) of 9.6%. Patient was proposed to intensify the treatment with insulin however he refused it. He was subsequently prescribed hydroxychloroquine 400 mg. Patient responded well to the therapy of hydroxy­chloroquine and subsequent follow-ups showed good glycaemic control. (Clin Diabetol 2017; 6, 6: 211–214)

Get Citation

Keywords

type 2 diabetes mellitus, hydroxychloroquine, oral hypoglycemic agents

About this article
Title

Improvement of type 2 diabetes mellitus control with hydroxychloroquine added to triple oral antidiabetis drugs: a case report

Journal

Clinical Diabetology

Issue

Vol 6, No 6 (2017)

Pages

211-214

Published online

2018-01-26

DOI

10.5603/DK.2017.0034

Bibliographic record

Clinical Diabetology 2017;6(6):211-214.

Keywords

type 2 diabetes mellitus
hydroxychloroquine
oral hypoglycemic agents

Authors

Subash Chandra Satpathy
Indranil Purkait
Avinash Talware

References (14)
  1. Wu Y, Ding Y, Tanaka Y, et al. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014; 11(11): 1185–1200.
  2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice. 1995; 28(2): 103–117.
  3. Kaplan YC, Ozsarfati J, Nickel C, et al. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016; 81(5): 835–848.
  4. Emami J, Gerstein HC, Pasutto FM, et al. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol. 1999; 77(2): 118–123.
  5. SMITH G, CHRISTENSEN J, RIDEOUT J, et al. Hepatic processing of insulin. Characterization of differential inhibition by weak bases. European Journal of Biochemistry. 1989; 181(2): 287–294.
  6. Wasko MC, McClure CK, Kelsey SF, et al. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015; 58(10): 2336–2343.
  7. Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012; 14(3): R135.
  8. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2): 187–193.
  9. Gerstein HC, Thorpe KE, Taylor DW, et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract. 2002; 55(3): 209–219.
  10. Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014; 30(7): 1257–1266.
  11. Padsalge M, Abhyankar M, Ghag S. Insulin sparing effect of hydroxychloroquine in uncontrolled diabetes mellitus. Clinical Diabetology. 2016; 5(4): 138–140.
  12. Bennett M. Antimalarials in dermatology. Current Problems in Dermatology. 2000; 12(6): 257–259.
  13. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110(7): 1321–1326.
  14. Marmor MF, Kellner U, Lai TYY, et al. American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6): 1386–1394.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl